Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions

Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtin, Sandra, Knop, Carol S., Milliron, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093357/
https://www.ncbi.nlm.nih.gov/pubmed/25031973
_version_ 1782325710994538496
author Kurtin, Sandra
Knop, Carol S.
Milliron, Todd
author_facet Kurtin, Sandra
Knop, Carol S.
Milliron, Todd
author_sort Kurtin, Sandra
collection PubMed
description Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery.
format Online
Article
Text
id pubmed-4093357
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40933572014-07-16 Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions Kurtin, Sandra Knop, Carol S. Milliron, Todd J Adv Pract Oncol Review Article Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery. Harborside Press 2012 2012-11-01 /pmc/articles/PMC4093357/ /pubmed/25031973 Text en Copyright © 2012, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Kurtin, Sandra
Knop, Carol S.
Milliron, Todd
Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title_full Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title_fullStr Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title_full_unstemmed Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title_short Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
title_sort subcutaneous administration of bortezomib: strategies to reduce injection site reactions
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093357/
https://www.ncbi.nlm.nih.gov/pubmed/25031973
work_keys_str_mv AT kurtinsandra subcutaneousadministrationofbortezomibstrategiestoreduceinjectionsitereactions
AT knopcarols subcutaneousadministrationofbortezomibstrategiestoreduceinjectionsitereactions
AT millirontodd subcutaneousadministrationofbortezomibstrategiestoreduceinjectionsitereactions

Ejemplares similares